Selpercatinib 40 & 80 mg is an innovative targeted therapy designed to inhibit RET gene mutations, providing a highly precise treatment option for patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancers. Now available as Selpercatinib 40 & 80 mg in India, it provides a cutting-edge option for cancer care. For more information click on this link-:https://www.impomedhealthcare.com/